Breaking News
5341 - 5355 of 6623 results
Prev
355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442
Next
September 21, 2007
Bioxel Pharma, Inc. has won its largest paclitaxel order—valued at about $800,000—from a multinational pharmaceutical company that is currently completing Phase III trials for a paclitaxel-based product. Paclitaxel deliveries under the o…
Read More »
September 21, 2007
DSM Pharmaceutical Products has made several management appointments. Mr. Leendert Staal, currently business group director DSM Pharmaceutical Products, will be appointed president of DSM Nutritional Products, reporting to Stephan Tanda, member of t…
Read More »
September 20, 2007
Millennium Pharmaceuticals achieved positive interim results from an international Phase III VISTA trial in patients with newly diagnosed multiple myeloma that showed Velcade therapy, melphalan and prednisone (VMP), demonstrated a statistically signi…
Read More »
September 20, 2007
MedImmune, Inc. received approval from the FDA for the expanded use of FluMist (Influenza Virus Vaccine Live, Intranasal) in children two to five years of age. FluMist is now approved for active immunization for the prevention of influenza A and B vi…
Read More »
September 20, 2007
ImClone Systems' anti-insulin-like growth factor-1 receptor (IGR-IR) monoclonal antibody (known as IMC-A12) has received 10 proposals for Phase I/II trials from the Cancer Therapy Evaluation Program (CTEP) of the Division of Cancer Treatment and Diag…
Read More »
September 19, 2007
Genzyme Corp. broke ground on a $150 million expansion project at its Allston Landing manufacturing facility in Boston that will add space for manufacturing support functions and will create 90 jobs.
Commercial production at Allston Landing, which…
Read More »
September 19, 2007
Catalent Pharma Solutions
4Q Revenues: $451.3 million (+5%)
4Q Loss: $168.7 million (earnings were $27.6 million 4Q2006)
FY Revenues: $1.7 billion (+6%)
FY Loss: $127.3 million (earnings were $51 million FY2006)
Comments: FY and 4Q revenue…
Read More »
September 19, 2007
Robert J. Heine, M.D., Ph.D., F.R.C.P., will join Eli Lilly and Co. in January, 2008, as executive medical director for the diabetes and endocrine division responsible for development of Lilly's expanding diabetes and obesity R&D portfolio. Dr. H…
Read More »
September 17, 2007
AstraZeneca is planning to outsource all drug manufacturing activities within 10 years, according to a company statement. "Manufacturing for AstraZeneca is not a core activity," said David Smith, AstraZeneca's executive vice-president of op…
Read More »
September 17, 2007
Celera has entered into a research collaboration with Merck to develop biomarker and pharmacogenomic tests for cancer patients. Under the terms of the agreement, Celera will evaluate certain gene expression profiles identified by Merck with the goal…
Read More »
September 17, 2007
The FDA has approved use of J&J's five-day, once-daily regimen of Levaquin 750 mg I.V. and oral, for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).
The approval is based on results from a double-bl…
Read More »
September 14, 2007
Accenture and Bristol-Myers Squibb have launched a joint center for pharmacovigilance in Chennai, India. The new center will be operated by more than 140 Accenture employees and will undertake the processing and coding of adverse event data and the g…
Read More »
September 14, 2007
Gene Logic, Inc. has entered into a collaboration with the FDA regarding quality control methods and metrics for understanding disparate genomic data sent as part of regulatory submissions. The collaboration is part of the FDA's Critical Path Initiat…
Read More »
September 14, 2007
Eli Lilly and Co. received approval from the FDA for its osteoporosis drug Evista for a new use to reduce the risk of invasive breast cancer in two populations: postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive…
Read More »
September 13, 2007
Daniel G. Darazsdi has been appointed chief financial officer, PPD, Inc., effective October 1. Mr. Darazsdi joins the company after 25 years with Honeywell International, where he most recently served as vice president and chief financial officer of…
Read More »
5341 - 5355 of 6623 results
Prev
355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442
Next
